Posted by Michael Wonder on 20 Feb 2018
The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges
20 February 2018 - Good practices for budget impact analysis have been increasingly developed since the year 2000.
As a financial approach, budget impact analysis (BIA) is currently mandatory to support manufacturers’ formulary submissions for national or provincial reimbursement in many countries (e.g. Canada, Belgium, Australia, and Poland).
The objective of this editorial is to provide a better understanding of the current use of budget impact analysis in four countries: Australia, England, France and the United States of America and to stress the “common” decision maker concerns and methodological issues related to BIA across these countries.
